Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The current proposal is designed as a first-in-human Phase 1 open-label, dose-escalation
study to assess the safety, pharmacokinetics, and the maximum tolerated dose of DHM among
healthy volunteers using a purified form of DHM from a local cGMP compliant source (Master
Herbs, Inc).